{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:13Z","timestamp":1790677393310,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alice and Y.-T. Chen Pediatric Genetics and Genomics Center","award":["R01-FD004364"],"award-info":[{"award-number":["R01-FD004364"]}]},{"name":"Food and Drug Administration","award":["R01-AR065873"],"award-info":[{"award-number":["R01-AR065873"]}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roivant Rare Diseases"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ymthe.2018.06.023","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T03:37:47Z","timestamp":1530761867000},"page":"2304-2314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I\/II Clinical Trial of Clenbuterol in Pompe Disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Dwight D.","family":"Koeberl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crista","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-oh","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Bursac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.06.023_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"\u03b22 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive \u03b22-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2018.06.023_bib4","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2018.06.023_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.06.023_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.archoralbio.2006.01.003","article-title":"The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat","volume":"51","author":"Matsumoto","year":"2006","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.healun.2008.01.013","article-title":"Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure","volume":"27","author":"Kamalakkannan","year":"2008","journal-title":"J.\u00a0Heart Lung Transplant."},{"key":"10.1016\/j.ymthe.2018.06.023_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1756285609103324","article-title":"Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II","volume":"2","author":"Angelini","year":"2009","journal-title":"Ther. Adv. Neurol. Disorder."},{"key":"10.1016\/j.ymthe.2018.06.023_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","article-title":"The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients","volume":"35","author":"van Capelle","year":"2012","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"1985","key":"10.1016\/j.ymthe.2018.06.023_bib11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1152\/jappl.1998.85.4.1337","article-title":"Fiber type and citrate synthase activity in the human gastrocnemius and vastus lateralis with aging","volume":"85","author":"Houmard","year":"1998","journal-title":"J.\u00a0Appl. Physiol"},{"key":"10.1016\/j.ymthe.2018.06.023_bib12","first-page":"621","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib13","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2018.06.023_bib14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.06.023_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10545-010-9204-5","article-title":"Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response","volume":"33","author":"Ravaglia","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2018.06.023_bib16","first-page":"91","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1468-1331.2008.02377.x","article-title":"Glycogen storage disease type II (Pompe disease)\u2014influence of enzyme replacement therapy in adults","volume":"16","author":"Merk","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2018.06.023_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.braindev.2011.05.004","article-title":"Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease","volume":"34","author":"Ishigaki","year":"2012","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymthe.2018.06.023_bib21","first-page":"952","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study","volume":"20","author":"van Capelle","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2018.06.023_bib23","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1183\/09031936.00169011","article-title":"Supine volume drop and diaphragmatic function in adults with Pompe disease","volume":"39","author":"Prigent","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymthe.2018.06.023_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1750-1172-8-160","article-title":"The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?","volume":"8","author":"Lachmann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2018.06.023_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study","volume":"119","author":"van der Ploeg","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ymthe.2017.02.017","article-title":"Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid \u03b1-Glucosidase in Pompe Patients Co-administered with Alglucosidase \u03b1","volume":"25","author":"Kishnani","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.06.023_bib27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib28","first-page":"71","article-title":"Adult acid maltase deficiency: an open trial with albuterol and branched-chain aminoacids","volume":"14","author":"Angelini","year":"2004","journal-title":"Basic Appl. Myol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib29","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2018.06.023_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000195203","article-title":"Study of the cardiovascular effects of clenbuterol in exercise-induced asthma","volume":"51","author":"Di Gioacchino","year":"1987","journal-title":"Respiration"},{"key":"10.1016\/j.ymthe.2018.06.023_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00563099","article-title":"Dose response relationship of clenbuterol (NAB 365) as a solution for inhalation","volume":"15","author":"Tschan","year":"1979","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib32","first-page":"176","article-title":"NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial","volume":"17","author":"Pasotti","year":"1979","journal-title":"Int. J. Clin. Pharmacol. Biopharm."},{"key":"10.1016\/j.ymthe.2018.06.023_bib33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/cs0840651","article-title":"Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients","volume":"84","author":"Maltin","year":"1993","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ymthe.2018.06.023_bib34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/bjsports-2014-093526","article-title":"Anabolic agents: recent strategies for their detection and protection from inadvertent doping","volume":"48","author":"Geyer","year":"2014","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.ymthe.2018.06.023_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2018.06.023_bib36","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2018.06.023_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.880060204","article-title":"Clinical investigation in Duchenne dystrophy: 2. Determination of the \u201cpower\u201d of therapeutic trials based on the natural history","volume":"6","author":"Brooke","year":"1983","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2018.06.023_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2018.06.023_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/002215540505300108","article-title":"High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology","volume":"53","author":"Lynch","year":"2005","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.ymthe.2018.06.023_bib40","unstructured":"Babraham Bioinformatics. (2012). Trim galore. http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/trim_galore."},{"key":"10.1016\/j.ymthe.2018.06.023_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"10.1016\/j.ymthe.2018.06.023_bib42","doi-asserted-by":"crossref","first-page":"D91","DOI":"10.1093\/nar\/gkr895","article-title":"Ensembl Genomes: an integrative resource for genome-scale data from non-vertebrate species","volume":"40","author":"Kersey","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2018.06.023_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2018.06.023_bib44","unstructured":"Anders, S. (2010). HTSeq. http:\/\/www-huber.embl.de\/users\/anders\/HTSeq\/."},{"key":"10.1016\/j.ymthe.2018.06.023_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2018.06.023_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nmeth.3252","article-title":"Orchestrating high-throughput genomic analysis with Bioconductor","volume":"12","author":"Huber","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2018.06.023_bib47","unstructured":"The R Foundation. (2004). The R project for statistical computing. https:\/\/www.r-project.org."},{"key":"10.1016\/j.ymthe.2018.06.023_bib48","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2018.06.023_bib49","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2018.06.023_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618303095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618303095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T19:36:49Z","timestamp":1589917009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618303095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525001618303095"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.023","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I\/II Clinical Trial of Clenbuterol in Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}